Intelligent deployment system of scientific applications in the cloud (TSI-100104-2015-27)
Acción Estratégica de Economía y Sociedad Digital - Impulso Tecnológico (A.E.E.S.D. - Impulso Tecnológico), financiación procedente del Fondo Europeo de Desarrollo Regional (FEDER)
Intelligent Pharma has been awarded by the Spanish Ministry of Industry (MINETUR) to develop new, advanced computational chemistry technologies in the cloud.
This project consists of the development of an intelligent system to deploy scientific applications in the cloud. Computational chemistry technologies are normally based on work-flows. This project will research, develop and validate a system to deploy such scientific work-flows in hybrid cloud computing systems, combining our own internal super-computational facilities and other cloud-based environments such as Amazon EC2 and the Google Compute Engine. The technology to be developed will significantly enhance Intelligent Pharma's productivity in the research and development of in silico research projects. The project started in July 2015 and will finish in June 2017.
Applied Health Technologies: DIALCAT project
A Intelligent Pharma leads a project positioned in the RIS3CAT community Applied Health Technologies: Diabetes as an accelerator of cognitive impairment and Alzheimer's disease: comprehensive approach and adherence to treatment (DIALCAT). The project has been awarded a total budget of 2.5 million € for the next 3 years.
Currently, there are robust epidemiological data that show patients with type 2 diabetes mellitus (DM2) have a 2-3 times higher prevalence of severe cognitive impairment and Alzheimer's disease (AD), compared to non-diabetic people. This group generates a health burden of approximately 5,500 million euros in Spain. DIALCAT proposes a comprehensive approach that includes observational clinical research, a pilot interventional study to improve metabolic control and the development and validation of an electronic dispenser that ensures and monitors the adherence to treatment as well as the health conditions of the patients. This new approach involves clinicians, caregivers, patients and pharmacists and has the ultimate goal to maximize the delay of the onset of AD.